The FDA has accepted the filing of an abbreviated new drug application (ANDA) for Lutetium Lu 177 Dotatate, a generic version of lutetium Lu 177 dotatate indicated for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.